title: Clinical study of efficacy of hydroxyapatite.
abstract: The cleaved part of collagen during collagen formation was secreted into the circulation. The present study used this remnant part of collagen called procollagen type 1 propeptide at carboxyl terminal (PICP) as a bone formation marker Clinical study of efficacy of hydroxyapatite tablet (800 mg) in 47 menopausal women with bone resorption marker, (CTx) below 0.330 ng/ml. and their general condition is healthy. All cases were free of medication at least one month before the present study. After one month, the mean of PICP was 1452.28 ng/ml SD = 625.58 which is significantly higher than the mean of baseline control, 930.98 ng/ml SD=477.44 (p=0.0001).
authors.affiliation: PrapinKloa Hospital.
authors.forename: Thaiyin
authors.initials: T
authors.lastname: Srimongkol
authors.forename: Narong
authors.initials: N
authors.lastname: Bunyaratavej
mesh_terms: D001672:Biocompatible Materials / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers; D001862:Bone Resorption; D001842:Bone and Bones / Q000187:drug effects*; D024042:Collagen Type I / Q000032:analysis*; D017886:Durapatite / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D001672:Biocompatible Materials; D015415:Biomarkers; D024042:Collagen Type I; D017886:Durapatite